Marvin A Konstam

Summary

Affiliation: Tufts-New England Medical Center
Country: USA

Publications

  1. ncbi request reprint Continuous aortic flow augmentation: a pilot study of hemodynamic and renal responses to a novel percutaneous intervention in decompensated heart failure
    Marvin A Konstam
    Tufts New England Medical Center, Tufts University, Boston, MA, USA
    Circulation 112:3107-14. 2005
  2. ncbi request reprint Endothelin expression and the progression of heart failure: exemplifying the vagaries of therapeutic development
    Marvin A Konstam
    Division of Cardiology, Department of Medicine, Tufts New England Medical Center and Tufts University School of Medicine, Boston, Mass, USA
    Circulation 109:143-5. 2004
  3. ncbi request reprint Aspirin and heart failure: square evidence meets a round patient
    Marvin A Konstam
    Division of Cardiology, Tufts New England Medical Center, Tufts University School of Medicine, Boston, MA 02111, USA
    Congest Heart Fail 9:203-5. 2003
  4. ncbi request reprint Heart failure training: a call for an integrative, patient-focused approach to an emerging cardiology subspecialty
    Marvin A Konstam
    Division of Cardiology, Department of Medicine, Tufts New England Medical Center, 750 Washington Street, Boston, Massachusetts 02111, USA
    J Am Coll Cardiol 44:1361-2. 2004
  5. ncbi request reprint Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial
    Marvin A Konstam
    Division of Cardiology, Tufts New England Medical Center, Boston, Mass, USA
    JAMA 297:1319-31. 2007
  6. ncbi request reprint Comparison of losartan and captopril on heart failure-related outcomes and symptoms from the losartan heart failure survival study (ELITE II)
    Marvin A Konstam
    Division of Cardiology, Tufts New England Medical Center, Boston, MA 02111, USA
    Am Heart J 150:123-31. 2005
  7. ncbi request reprint Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST)
    Mihai Gheorghiade
    Division of Cardiology, Northwestern Feinberg School of Medicine, Chicago, IL, USA
    J Card Fail 11:260-9. 2005
  8. ncbi request reprint Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials
    Mihai Gheorghiade
    Division of Cardiology, Northwestern University, Feinberg School of Medicine, Chicago, Ill 60611, USA
    JAMA 297:1332-43. 2007
  9. ncbi request reprint Randomized, controlled evaluation of short- and long-term benefits of heart failure disease management within a diverse provider network: the SPAN-CHF trial
    Carey Kimmelstiel
    Division of Cardiology, Tufts New England Medical Center, and Tufts University School of Medicine, Boston, Mass 02111, USA
    Circulation 110:1450-5. 2004
  10. doi request reprint Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial
    James E Udelson
    Division of Cardiology, Tufts Medical Center, Boston, Massachusetts 02111, USA
    J Am Coll Cardiol 52:1540-5. 2008

Detail Information

Publications47

  1. ncbi request reprint Continuous aortic flow augmentation: a pilot study of hemodynamic and renal responses to a novel percutaneous intervention in decompensated heart failure
    Marvin A Konstam
    Tufts New England Medical Center, Tufts University, Boston, MA, USA
    Circulation 112:3107-14. 2005
    ....
  2. ncbi request reprint Endothelin expression and the progression of heart failure: exemplifying the vagaries of therapeutic development
    Marvin A Konstam
    Division of Cardiology, Department of Medicine, Tufts New England Medical Center and Tufts University School of Medicine, Boston, Mass, USA
    Circulation 109:143-5. 2004
  3. ncbi request reprint Aspirin and heart failure: square evidence meets a round patient
    Marvin A Konstam
    Division of Cardiology, Tufts New England Medical Center, Tufts University School of Medicine, Boston, MA 02111, USA
    Congest Heart Fail 9:203-5. 2003
  4. ncbi request reprint Heart failure training: a call for an integrative, patient-focused approach to an emerging cardiology subspecialty
    Marvin A Konstam
    Division of Cardiology, Department of Medicine, Tufts New England Medical Center, 750 Washington Street, Boston, Massachusetts 02111, USA
    J Am Coll Cardiol 44:1361-2. 2004
    ....
  5. ncbi request reprint Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial
    Marvin A Konstam
    Division of Cardiology, Tufts New England Medical Center, Boston, Mass, USA
    JAMA 297:1319-31. 2007
    ..Vasopressin mediates fluid retention in heart failure. Tolvaptan, a vasopressin V2 receptor blocker, shows promise for management of heart failure...
  6. ncbi request reprint Comparison of losartan and captopril on heart failure-related outcomes and symptoms from the losartan heart failure survival study (ELITE II)
    Marvin A Konstam
    Division of Cardiology, Tufts New England Medical Center, Boston, MA 02111, USA
    Am Heart J 150:123-31. 2005
    ..We compared effects of losartan to captopril on mortality, morbidity, and functional status for patients in the ELITE II study...
  7. ncbi request reprint Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST)
    Mihai Gheorghiade
    Division of Cardiology, Northwestern Feinberg School of Medicine, Chicago, IL, USA
    J Card Fail 11:260-9. 2005
    ....
  8. ncbi request reprint Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials
    Mihai Gheorghiade
    Division of Cardiology, Northwestern University, Feinberg School of Medicine, Chicago, Ill 60611, USA
    JAMA 297:1332-43. 2007
    ..Heart failure causes more than 1 million US hospitalizations yearly, mostly related to congestion. Tolvaptan, an oral, nonpeptide, selective vasopressin V2-receptor antagonist, shows promise in this condition...
  9. ncbi request reprint Randomized, controlled evaluation of short- and long-term benefits of heart failure disease management within a diverse provider network: the SPAN-CHF trial
    Carey Kimmelstiel
    Division of Cardiology, Tufts New England Medical Center, and Tufts University School of Medicine, Boston, Mass 02111, USA
    Circulation 110:1450-5. 2004
    ..Most of these studies are limited by small sample size; absence of concurrent, randomized controls; limited follow-up; restriction to urban academic centers; and low baseline use of effective medications...
  10. doi request reprint Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial
    James E Udelson
    Division of Cardiology, Tufts Medical Center, Boston, Massachusetts 02111, USA
    J Am Coll Cardiol 52:1540-5. 2008
    ..This study sought to assess the acute hemodynamic effect of vasopressin V(2) receptor antagonism...
  11. ncbi request reprint Enalapril treatment and hospitalization with atrial tachyarrhythmias in patients with left ventricular dysfunction
    Alawi A Alsheikh-Ali
    Tufts New England Medical Center, Department of Medicine, Division of Cardiolgy, Boston, Mass, USA
    Am Heart J 147:1061-5. 2004
    ..We sought to determine whether enalapril treatment reduced hospitalizations with atrial tachyarrhythmias in patients with LV dysfunction...
  12. ncbi request reprint Ventricular assist device therapy normalizes inducible nitric oxide synthase expression and reduces cardiomyocyte apoptosis in the failing human heart
    Richard D Patten
    Molecular Cardiology Research Institute, Tufts New England Medical Center, Boston, Massachusetts 02111, USA
    J Am Coll Cardiol 45:1419-24. 2005
    ..We examined the effect of mechanical unloading with ventricular assist device (VAD) therapy on myocardial inducible nitric oxide synthase (iNOS) expression and cardiomyocyte apoptosis in patients with end-stage heart failure (HF)...
  13. ncbi request reprint Hospital cost effect of a heart failure disease management program: the Specialized Primary and Networked Care in Heart Failure (SPAN-CHF) trial
    Douglas Gregory
    Cardiovascular Clinical Studies, Boston, MA 02111, USA
    Am Heart J 151:1013-8. 2006
    ..Determine the effect on hospitalization cost of a heart failure disease management (HFDM) program delivered within a diverse provider network as demonstrated in the SPAN-CHF randomized controlled trial...
  14. ncbi request reprint Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction
    James E Udelson
    Division of Cardiology, Tufts New England Medical Center Tufts University School of Medicine, Boston, Massachusetts 02111, USA
    J Am Coll Cardiol 49:2151-9. 2007
    ..This study sought to examine the effects of vasopressin V2 receptor antagonism with tolvaptan on the changes in left ventricular (LV) volumes over time...
  15. ncbi request reprint New concepts in post-infarction ventricular remodeling
    James E Udelson
    Division of Cardiology, Tufts New England Medical Center, Tufts University School of Medicine, Boston, Massachusetts, USA
    Rev Cardiovasc Med 4:S3-12. 2003
    ..It is also demonstrated that drug therapies that slow or reverse the remodeling process appear to have favorable natural history effects in the short term as well as during long-term therapy...
  16. doi request reprint Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction
    James E Udelson
    Tufts Medical Center, 750 Washington Street, Boston, MA 02111, USA
    Circ Heart Fail 3:347-53. 2010
    ..Few data are available on effects of aldosterone antagonism in patients with mild-to-moderate HF...
  17. ncbi request reprint Effects of angiotensin II receptor blockade versus angiotensin-converting-enzyme inhibition on ventricular remodelling following myocardial infarction in the mouse
    Richard D Patten
    Molecular Cardiology Research Institute, New England Medical Center, 750 Washington Street, Boston, MA 02111, USA
    Clin Sci (Lond) 104:109-18. 2003
    ..These results serve as an important basis for planned investigations to evaluate the anti-remodelling effects of these agents on mice in which genetic manipulations are used to disrupt components of the Ang II signalling system...
  18. ncbi request reprint Relation between left ventricular remodeling and clinical outcomes in heart failure patients with left ventricular systolic dysfunction
    James E Udelson
    Division of Cardiology, Tufts New England Medical Center, Tufts University School of Medicine, Boston, MA, USA
    J Card Fail 8:S465-71. 2002
    ..After any insult to the left ventricle resulting in diminished systolic performance and stroke volume, a series of histopathologic changes in the myocardium and structural changes in the LV chamber occurs over time...
  19. ncbi request reprint The economic effect of a tertiary hospital-based heart failure program
    Douglas Gregory
    Cardiovascular Clinical Studies and Tufts University School of Medicine, Boston, Massachusetts, USA
    J Am Coll Cardiol 46:660-6. 2005
    ..This study was designed to determine the economic effect of a tertiary heart failure (HF) program at an academic medical center...
  20. ncbi request reprint Peripheral vascular endothelial function correlates with exercise capacity in cardiac transplant recipients
    Ayan R Patel
    Division of Cardiology Department of Medicine, Molecular Cardiology Research Institute, Tufts New England Medical Center, Boston, Massachusetts 02111, USA
    Am J Cardiol 91:897-9. 2003
  21. ncbi request reprint Improving clinical outcomes with drug treatment in heart failure: what have trials taught?
    Marvin A Konstam
    Department of Medicine, Division of Cardiology, Tufts New England Medical Center and Tufts University School of Medicine, Boston, Massachusetts, USA
    Am J Cardiol 91:9D-14D. 2003
    ..Clinical trials have provided significant treatment advances; ongoing and future trials will demonstrate the degree to which we can improve on what we have achieved to date with pharmacologic treatments...
  22. doi request reprint Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach
    Daniel G Kramer
    Division of Cardiology and the CardioVascular Center, Tufts Medical Center, Boston, Massachusetts 02111, USA
    J Am Coll Cardiol 56:392-406. 2010
    ..The purpose of this study was to quantitatively assess the relationship between therapy-induced changes in left ventricular (LV) remodeling and longer-term outcomes in patients with left ventricular dysfunction (LVD)...
  23. ncbi request reprint Impact of chronic kidney disease and anemia on hospitalization expense in patients with left ventricular dysfunction
    Douglas D Gregory
    Division of Clinical Decision Making, Tufts University School of Medicine, Boston, Massachusetts 02111, USA
    Am J Cardiol 92:1300-5. 2003
    ....
  24. ncbi request reprint Gender-specific patterns of left ventricular and myocyte remodeling following myocardial infarction in mice deficient in the angiotensin II type 1a receptor
    Paul Bridgman
    Molecular Cardiology Research Institute, Tufts New England Medical Center, Box 80, 750 Washington St, Boston, MA 02111, USA
    Am J Physiol Heart Circ Physiol 289:H586-92. 2005
    ..Further work is necessary to explore the potential mechanisms underlying these gender-based differences...
  25. doi request reprint Weight changes after hospitalization for worsening heart failure and subsequent re-hospitalization and mortality in the EVEREST trial
    John E A Blair
    Division of Cardiology, Northwestern University Feinberg School of Medicine, 676 North Saint Clair, Suite 600, Chicago, IL 60611, USA
    Eur Heart J 30:1666-73. 2009
    ..We explore the relationship between change in BW after hospitalization for worsening HF and risk for repeat hospitalization and mortality in the EVEREST trial...
  26. doi request reprint Design of the heart failure endpoint evaluation of AII-antagonist losartan (HEAAL) study in patients intolerant to ACE-inhibitor
    Marvin A Konstam
    Tufts Medical Center, Boston, MA 02111, USA
    Eur J Heart Fail 10:899-906. 2008
    ....
  27. ncbi request reprint Comparison of survival and other complications after heart transplantation in patients taking amiodarone before surgery versus those not taking amiodarone
    Patrick J Blomberg
    Division of Cardiology, Tufts University Medical School, Tufts New England Medical Center, Boston, Massachusetts, USA
    Am J Cardiol 93:379-81. 2004
    ..These findings raise further concern about the use of amiodarone treatment in patients with heart failure before undergoing HT...
  28. doi request reprint The effect of ventricular assist devices on post-transplant mortality an analysis of the United network for organ sharing thoracic registry
    Vishnu Patlolla
    Department of Medicine, Division of Cardiovascular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA
    J Am Coll Cardiol 53:264-71. 2009
    ..This study sought to determine the relationship between pre-transplant ventricular assist device (VAD) support and mortality after heart transplantation...
  29. ncbi request reprint Contemporary medical options for treating patients with heart failure
    Marvin A Konstam
    Department of Medicine, Division of Cardiology, Tufts New England Medical Center, and Tufts University School of Medicine, Boston, Mass 02111, USA
    Circulation 105:2244-6. 2002
  30. doi request reprint Advanced heart failure and transplant cardiology: a subspecialty is born
    Marvin A Konstam
    Cardiovascular Center, Tufts Medical Center, Boston, Massachusetts 02111, USA
    J Am Coll Cardiol 53:834-6. 2009
    ..In the years to come, the specialty must adapt to the ongoing rapid expansion of evidence-based knowledge in this field to continue to provide the highest level of care and the best outcomes to patients with heart failure...
  31. doi request reprint Advanced heart failure and transplant cardiology: a subspecialty is born
    Marvin A Konstam
    Cardiovascular Center, Tufts Medical Center, Boston, Massachusetts 02111, USA
    J Card Fail 15:98-100. 2009
    ..In the years to come, the specialty must adapt to the ongoing rapid expansion of evidence-based knowledge in this field to continue to provide the highest level of care and the best outcomes to patients with heart failure...
  32. doi request reprint A cost-saving strategy for inpatient management of advanced decompensated heart failure patients: the Cardiomyopathy Unit
    Douglas Gregory
    Cardiovascular Clinical Studies, Boston, MA 02111, USA
    J Card Fail 15:428-34. 2009
    ..This article analyzes the relative costs and revenues of the Tufts Medical Center Cardiomyopathy Unit (CMU), a recent innovation for grouping and managing advanced decompensated heart failure patients...
  33. ncbi request reprint Prevention and reversal of left ventricular remodeling: summation
    Marvin A Konstam
    Department of Medicine, Division of Cardiology, Tufts New England Medical Center and Tufts University School of Medicine, Boston, Massachusetts 02111, USA
    J Card Fail 8:S506-11. 2002
  34. ncbi request reprint Recent advances in the treatment of heart failure
    Ayan R Patel
    Division of Cardiology, New England Medical Center and Tufts University, Boston, Massachusetts 02111, USA
    Circ J 66:117-21. 2002
    ..As the importance of neurohormonal activation in the progression of heart failure becomes increasingly apparent, new therapeutic strategies targeting these neurohormonal systems are being investigated...
  35. ncbi request reprint Noninvasive assessment of left ventricular remodeling: concepts, techniques, and implications for clinical trials
    Inder S Anand
    Division of Cardiology, University of Minnesota Medical School and Veterans Administration Medical Center, Minneapolis, MN 55417, USA
    J Card Fail 8:S452-64. 2002
    ..Thus, to study the process of remodeling in practice and in clinical trials, we have relied on assessments and measurements derived from cardiac imaging tests...
  36. doi request reprint Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial
    Marvin A Konstam
    Tufts Medical Center, Tufts University School of Medicine, Boston, MA, USA
    Lancet 374:1840-8. 2009
    ..We compared the effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure...
  37. doi request reprint Emerging ventricular assist devices for long-term cardiac support
    Rajan Krishnamani
    The Cardiovascular Center, Tufts Medical Center, Boston, MA 02111, USA
    Nat Rev Cardiol 7:71-6. 2010
    ..These devices are at various stages of development and clinical investigation. One or more of these newer devices is likely to emerge as an important development in the treatment of patients with advanced heart failure...
  38. ncbi request reprint Fatty infiltration of right ventricle (adipositas cordis): an unrecognized cause of early graft failure after cardiac transplantation
    Rajan Krishnamani
    Department of Medicine, Division of Cardiology, Tufts New England Medical Center, Boston, MA 02111, USA
    J Heart Lung Transplant 24:1143-5. 2005
    ..If the diagnosis of fatty infiltration is suspected at time of donor harvest, the relative risks and benefits of proceeding with transplantation should be carefully assessed...
  39. doi request reprint A multicenter randomized controlled evaluation of automated home monitoring and telephonic disease management in patients recently hospitalized for congestive heart failure: the SPAN-CHF II trial
    Andrew Weintraub
    Division of Cardiology, Tufts Medical Center, Boston, MA, USA
    J Card Fail 16:285-92. 2010
    ..The AHM system measured and transmitted body weight, blood pressure, and heart rate data as well as subjective patient self-assessments via a standard telephone line to a central server...
  40. ncbi request reprint Acute heart failure syndromes: current state and framework for future research
    Mihai Gheorghiade
    Division of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
    Circulation 112:3958-68. 2005
  41. ncbi request reprint Aligning quality and payment for heart failure care: defining the challenges
    Edward P Havranek
    Division of Cardiology, Department of Medicine, Denver Health Medical Center and University of Colorado HSC, Denver, Colorado 80204 4507, USA
    J Card Fail 9:251-4. 2003
    ..This article describes each of these challenges in turn...
  42. doi request reprint Influence of donor cocaine use on outcome after cardiac transplantation: analysis of the United Network for Organ Sharing Thoracic Registry
    Andreas Brieke
    Division of Cardiology, University of Colorado at Denver and Health Sciences Center, Aurora, Colorado 80045, USA
    J Heart Lung Transplant 27:1350-2. 2008
    ....
  43. doi request reprint Arginine vasopressin antagonists for the treatment of heart failure and hyponatremia
    John J Finley
    Division of Cardiology and Department of Medicine, Tufts Medical Center, Boston, Mass 02111, USA
    Circulation 118:410-21. 2008
  44. ncbi request reprint Should beta-blockers be given to patients with heart disease and peanut-induced anaphylaxis? A decision analysis
    John A TenBrook
    Division of Clinical Decision Making, Informatics, and Telemedicine, Department of Medicine, Tufts New England Medical Center, 750 Washington Street, Boston, MA 02111, USA
    J Allergy Clin Immunol 113:977-82. 2004
    ..Beta-blocker therapy postmyocardial infarction is generally recommended because it reduces mortality. However, beta-blockers may increase anaphylaxis mortality in the growing population of patients with peanut-induced anaphylaxis...
  45. ncbi request reprint Novel neurohormonal antagonist strategies: vasopressin antagonism, anticytokine therapy, and endothelin antagonism in patients who have heart failure
    Olaf Hedrich
    Tufts New England Medical Center and Tufts University School of Medicine, Boston, MA 02111, USA
    Heart Fail Clin 1:103-27. 2005
  46. ncbi request reprint Reversal of left ventricular remodeling by pericardial tamponade
    Prem Soman
    Division of Cardiology, Tufts New England Medical Center, Boston, MA 02451, USA
    J Card Fail 11:131-3. 2005
  47. doi request reprint Transforming health care through the medical home: the example of heart failure
    Marvin A Konstam
    The Cardiovascular Center, Tufts Medical Center, and Tufts University, Boston, MA 02111, USA
    J Card Fail 15:736-8. 2009
    ....